...
search icon
ptgx-img

Protagonist Therapeutics Inc Share Price

PTGX
NMQ
$81.49
-$0.44
(-0.54%)
1D
Industry: Biotechnology Sector: Health Care

Protagonist Therapeutics Inc Analyst Forecast

Protagonist Therapeutics Inc Share Price Chart

Protagonist Therapeutics Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$5.12B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
124.1364
Volume info-icon
This is the total number of shares traded during the most recent trading day.
428.85K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.25
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$33.7 L
$96.54 H
$81.49

About Protagonist Therapeutics Inc, Common Stock

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. more

Industry: BiotechnologySector: Health Care

Protagonist Therapeutics Inc Stock Returns

Time FramePTGXSectorS&P500
1-Week Return-3.55%-1.08%-1.38%
1-Month Return0.16%-0.47%-1.81%
3-Month Return-2.1%2.13%1.38%
6-Month Return43.67%17.04%5.68%
1-Year Return110.68%6.56%11.74%
3-Year Return408.04%16.78%65.15%
5-Year Return201.59%34.34%73.68%
10-Year Return596.5%137.88%260.03%

Protagonist Therapeutics Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue28.63M27.36M26.58M60.00M434.43M[{"date":"2020-12-31","value":6.59,"profit":true},{"date":"2021-12-31","value":6.3,"profit":true},{"date":"2022-12-31","value":6.12,"profit":true},{"date":"2023-12-31","value":13.81,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue-2.77M1.03M3.31M2.96M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":83.79,"profit":true},{"date":"2022-12-31","value":31.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":89.46,"profit":true}]
Gross Profit28.63M27.36M26.58M60.00M434.43M[{"date":"2020-12-31","value":6.59,"profit":true},{"date":"2021-12-31","value":6.3,"profit":true},{"date":"2022-12-31","value":6.12,"profit":true},{"date":"2023-12-31","value":13.81,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin100.00%100.00%100.00%100.00%100.00%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses93.14M153.20M157.95M153.65M181.59M[{"date":"2020-12-31","value":51.29,"profit":true},{"date":"2021-12-31","value":84.37,"profit":true},{"date":"2022-12-31","value":86.98,"profit":true},{"date":"2023-12-31","value":84.61,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(64.52M)(125.84M)(131.37M)(93.65M)252.84M[{"date":"2020-12-31","value":-25.52,"profit":false},{"date":"2021-12-31","value":-49.77,"profit":false},{"date":"2022-12-31","value":-51.96,"profit":false},{"date":"2023-12-31","value":-37.04,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense(27.00K)737.00K8.04M27.60M52.88M[{"date":"2020-12-31","value":-0.05,"profit":false},{"date":"2021-12-31","value":1.39,"profit":true},{"date":"2022-12-31","value":15.2,"profit":true},{"date":"2023-12-31","value":52.2,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(64.84M)(125.55M)(127.39M)(78.95M)279.41M[{"date":"2020-12-31","value":-23.21,"profit":false},{"date":"2021-12-31","value":-44.93,"profit":false},{"date":"2022-12-31","value":-45.59,"profit":false},{"date":"2023-12-31","value":-28.26,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income Taxes1.30M(2.92M)(3.98M)(14.90M)4.22M[{"date":"2020-12-31","value":30.92,"profit":true},{"date":"2021-12-31","value":-69.29,"profit":false},{"date":"2022-12-31","value":-94.31,"profit":false},{"date":"2023-12-31","value":-353.03,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes(66.15M)(122.63M)(123.41M)(64.06M)275.19M[{"date":"2020-12-31","value":-24.04,"profit":false},{"date":"2021-12-31","value":-44.56,"profit":false},{"date":"2022-12-31","value":-44.85,"profit":false},{"date":"2023-12-31","value":-23.28,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income From Continuous Operations(66.15M)(125.55M)(127.39M)(140.48M)275.19M[{"date":"2020-12-31","value":-24.04,"profit":false},{"date":"2021-12-31","value":-45.62,"profit":false},{"date":"2022-12-31","value":-46.29,"profit":false},{"date":"2023-12-31","value":-51.05,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(66.15M)(125.55M)(123.41M)(78.95M)275.19M[{"date":"2020-12-31","value":-24.04,"profit":false},{"date":"2021-12-31","value":-45.62,"profit":false},{"date":"2022-12-31","value":-44.85,"profit":false},{"date":"2023-12-31","value":-28.69,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
EPS (Diluted)(2.02)(2.70)(2.60)(1.49)4.20[{"date":"2020-12-31","value":-48.1,"profit":false},{"date":"2021-12-31","value":-64.29,"profit":false},{"date":"2022-12-31","value":-61.9,"profit":false},{"date":"2023-12-31","value":-35.48,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]

Protagonist Therapeutics Inc Ratios

Protagonist Therapeutics Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

PTGX
Cash Ratio 12.82
Current Ratio 13.05

Protagonist Therapeutics Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

PTGX
ROA (LTM) 1.82%
ROE (LTM) 7.80%

Protagonist Therapeutics Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

PTGX
Debt Ratio Lower is generally better. Negative is bad. 0.08
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.92

Protagonist Therapeutics Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

PTGX
Trailing PE 124.14
Forward PE 24.10
P/S (TTM) 24.48
P/B 7.93
Price/FCF NM
EV/R 21.77
EV/Ebitda 209.95
PEG NM

FAQs

What is Protagonist Therapeutics Inc share price today?

Protagonist Therapeutics Inc (PTGX) share price today is $81.49

Can Indians buy Protagonist Therapeutics Inc shares?

Yes, Indians can buy shares of Protagonist Therapeutics Inc (PTGX) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PTGX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Protagonist Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Protagonist Therapeutics Inc (PTGX) via the Vested app. You can start investing in Protagonist Therapeutics Inc (PTGX) with a minimum investment of $1.

How to invest in Protagonist Therapeutics Inc shares from India?

You can invest in shares of Protagonist Therapeutics Inc (PTGX) via Vested in three simple steps:

  • Click on Sign Up or Invest in PTGX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Protagonist Therapeutics Inc shares
What is Protagonist Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Protagonist Therapeutics Inc (PTGX) is $96.54. The 52-week low price of Protagonist Therapeutics Inc (PTGX) is $33.7.

What is Protagonist Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Protagonist Therapeutics Inc (PTGX) is 124.1364

What is Protagonist Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Protagonist Therapeutics Inc (PTGX) is 7.93

What is Protagonist Therapeutics Inc dividend yield?

The dividend yield of Protagonist Therapeutics Inc (PTGX) is 0.00%

What is the Market Cap of Protagonist Therapeutics Inc?

The market capitalization of Protagonist Therapeutics Inc (PTGX) is $5.12B

What is Protagonist Therapeutics Inc's stock symbol?

The stock symbol (or ticker) of Protagonist Therapeutics Inc is PTGX

How Can Investors Use Protagonist Therapeutics Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Protagonist Therapeutics Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Protagonist Therapeutics Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Protagonist Therapeutics Inc shares for Indian investors?

When investing in Protagonist Therapeutics Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Protagonist Therapeutics Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Protagonist Therapeutics Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Protagonist Therapeutics Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Protagonist Therapeutics Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top